Overview

• The $600 million injection values Neuralink at $9 billion, more than doubling its worth since late 2023.
• Implants in three patients, including a non-verbal man with ALS, have enabled users to play video games, browse the internet and communicate via cursor control.
• The FDA granted the brain-computer interface its breakthrough device designation earlier this month, accelerating the startup’s regulatory pathway.
• Neuralink plans to begin clinical trials for its Blindsight implant by 2026, targeting complete vision restoration for blind individuals.
• The company still faces ethical scrutiny and regulatory hurdles as it explores wider medical applications and potential consumer use cases.